BOSTON — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing next-generation oligonucleotide therapies for severe neuromuscular and neurological diseases, announced that the United States Patent and Trademark Office (USPTO) has issued a new composition of matter patent covering its novel PGN-EDODM1 molecule.
The patent, which protects the composition of PGN-EDODM1 and its underlying chemistry, is expected to provide exclusivity in the United States through the second half of 2042, with the potential for additional patent term extension following FDA approval. The PGN-EDODM1 molecule leverages PepGen’s proprietary Enhanced Delivery Oligonucleotide (EDO) platform, which combines unique peptide and linker chemistry to improve the delivery of oligonucleotide-based therapies to target tissues.
“This patent protection underscores the novelty and differentiation of our peptide-conjugated oligonucleotide candidate, PGN-EDODM1, which is designed to address myotonic dystrophy type 1 — a severe neuromuscular disease with no approved therapies that target its underlying cause,” said James McArthur, Ph.D., President and CEO of PepGen. “Expanding our patent portfolio represents an important milestone that supports the long-term clinical and commercial potential of this program.”
The newly issued U.S. patent (Patent No. 12,465,646) strengthens PepGen’s growing global intellectual property portfolio, which includes multiple issued and pending patents covering the company’s innovative EDO platform and therapeutic candidates.
